Education
About Us
Working with TipRanks
Follow Us
Solvonis Therapeutics plc (GB:SVNS)
:SVNS
Total Valuation
Solvonis Therapeutics has a market cap or net worth of £19.87M. The enterprise value is 6.56M.
Market Cap£19.87M
Enterprise Value6.56M
Share Statistics
Solvonis Therapeutics has 6,806,403,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,806,403,300
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Solvonis Therapeutics’s return on equity (ROE) is -1.54 and return on invested capital (ROIC) is -151.31%.
Return on Equity (ROE)-1.54
Return on Assets (ROA)-1.28
Return on Invested Capital (ROIC)-151.31%
Return on Capital Employed (ROCE)-1.52
Revenue Per Employee195.67K
Profits Per Employee-1.04M
Employee Count3
Asset Turnover0.24
Inventory Turnover8.75
Valuation Ratios
The current PE Ratio of Solvonis Therapeutics is ―. Solvonis Therapeutics’s PEG ratio is -0.01.
PE Ratio―
PS Ratio1.02
PB Ratio0.30
Price to Fair Value0.30
Price to FCF-0.41
Price to Operating Cash Flow-0.53
PEG Ratio-0.01
Income Statement
In the last 12 months, Solvonis Therapeutics had revenue of 587.00K and earned -3.12M in profits. Earnings per share was -0.03.
Revenue587.00K
Gross Profit-134.00K
Operating Income-3.12M
Pretax Income-3.12M
Net Income-3.12M
EBITDA-2.94M
Earnings Per Share (EPS)-0.03
Cash Flow
In the last 12 months, operating cash flow was -572.00K and capital expenditures -4.00K, giving a free cash flow of -576.00K billion.
Operating Cash Flow-572.00K
Free Cash Flow-576.00K
Free Cash Flow per Share>-0.01
Dividends & Yields
Solvonis Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-2.33
52-Week Price Change85.99%
50-Day Moving Average0.33
200-Day Moving Average0.24
Relative Strength Index (RSI)35.80
Average Volume (3m)45.11M
Important Dates
Solvonis Therapeutics upcoming earnings date is Jul 1, 2026, Before Open (Not Confirmed).
Last Earnings DateSep 30, 2025
Next Earnings DateJul 1, 2026
Ex-Dividend Date―
Financial Position
Solvonis Therapeutics as a current ratio of 0.81, with Debt / Equity ratio of 0.00%
Current Ratio0.81
Quick Ratio0.68
Debt to Market Cap0.00
Net Debt to EBITDA0.04
Interest Coverage Ratio-1.04K
Taxes
In the past 12 months, Solvonis Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Solvonis Therapeutics EV to EBITDA ratio is -0.16, with an EV/FCF ratio of -0.32.
EV to Sales0.81
EV to EBITDA-0.16
EV to Free Cash Flow-0.32
EV to Operating Cash Flow-0.39
Balance Sheet
Solvonis Therapeutics has £757.00K in cash and marketable securities with £0.00 in debt, giving a net cash position of £757.00K billion.
Cash & Marketable Securities£757.00K
Total Debt£0.00
Net Cash£757.00K
Net Cash Per Share<£0.01
Tangible Book Value Per Share>-£0.01
Margins
Gross margin is 0.00%, with operating margin of -531.01%, and net profit margin of -531.52%.
Gross Margin0.00%
Operating Margin-531.01%
Pretax Margin-531.52%
Net Profit Margin-531.52%
EBITDA Margin-500.51%
EBIT Margin-531.01%
Analyst Forecast
The average price target for Solvonis Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―